SynDermix announces the sale of a majority stake of SDX Cosmetics – formerly a fully owned subsidiary of SynDermix AG.
ZURICH, SWITZERLAND — 10 April 2019
The Board of SynDermix is pleased to announce the sale of a majority stake in SDX Cosmetics — formerly a fully owned subsidiary of SynDermix AG and the driver for the sale and commercialisation of Énielle®, the Company’s proprietary skin serum and first wellcare product. SynDermix AG will remain a 20% shareholder of SDX Cosmetics, while SynDermix Management AG has established a Management Service Agreement with SDX-Cosmetics and will continue to advise on the further development of Énielle®.
About SynDermix AG
SynDermix AG is a Swiss developer of innovative health technologies funded by private investors. The Company focuses on the development of effective and safe treatments that meaningfully respect patient convenience and address important unmet medical needs.
SynDermix has built a diversified portfolio of innovative assets which correspond to three distinct proprietary technology platforms: smart medical devices based on digital acoustic modulation; drugs and medical devices based on a topical nitric oxide-releasing formulation; and drug candidates based on a recombinant plant lectin. Its business model is to a large extent virtual, driven by a strategy of in-licensing, outsourcing and out-licensing; the Company enters into strategic partnerships with third parties for the acquisition, development and commercialisation of a robust portfolio of assets with high innovation value and commercial potential. For more information please visit: www.syndermix.ch
SynDermix Management AG
+41 44 366 40 16